3月3日 - ** Emergent BioSolutions EBS.N股价在延时交易中下跌12.5%，至5.98美元，为9月份以来最低点
** 公司报告第四季度收入下降，为1.947亿美元，低于去年同期的2.766亿美元
** 经调整后，公司每股收益为 5 美分，而去年同期亏损 77 美分
** 公司正在推进扭亏为盈活动，这是其多年转型计划的关键阶段 - EBS
** 公司股价在 2024 年上涨 298.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.